Ligand Pharmaceuticals LGND Development, regulatory, & commercial milestones and tiered royalties — Investments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Investments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments?
- Ligand Pharmaceuticals (LGND) reported development, regulatory, & commercial milestones and tiered royalties — investments of $375M in Q1 2026.
- How has Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments changed year-over-year?
- Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments decreased by 0.0% year-over-year, from $375M to $375M.
- What is the long-term trend for Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's development, regulatory, & commercial milestones and tiered royalties — investments has grown at a 0.0% compound annual growth rate (CAGR), from $1.5B to $1.5B.
- What does development, regulatory, & commercial milestones and tiered royalties — investments mean?
- This metric represents the revenue generated from contractual milestone payments and tiered royalty streams associated with licensed pharmaceutical technologies and drug candidates. It reflects the financial performance of the company's core business model of monetizing intellectual property through partnerships with other biotechnology and pharmaceutical firms. By tracking these inflows, investors can assess the commercial success and regulatory progress of the underlying drug programs within the company's portfolio.